Skip to content

13F-HR filed by Lynx1 Capital Management LP

Lynx1 Capital Management LP filed this 13F-HR for the quarter ended 2022-09-30, filed 2022-11-14, with 12 holding rows worth $110,867,000.

Accession
0001892688-22-000084
Filed
2022-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2022

A holdings report, 12 entries on the cover page, a total value of $110,867,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $110,867,000 with VALUE read as thousands by filing date, 13F file number 028-22151. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BELLUS HEALTH INC NEW07987C204COM2,382,127$25,155,000thousands by filing date
ALPINE IMMUNE SCIENCES INC02083G100COM3,056,420$22,006,000thousands by filing date
KINNATE BIOPHARMA INC49705R105COM1,674,677$20,012,000thousands by filing date
MERUS N VN5749R100COM613,071$12,280,000thousands by filing date
CYMABAY THERAPEUTICS INC23257D103COM2,325,833$8,140,000thousands by filing date
AEROVATE THERAPEUTICS INC008064107COM276,447$4,583,000thousands by filing date
PARDES BIOSCIENCES INC69945Q105COM2,275,732$4,210,000thousands by filing date
PIERIS PHARMACEUTICALS INC720795103COM3,515,140$4,042,000thousands by filing date
PASSAGE BIO INC702712100COM2,752,422$3,441,000thousands by filing date
IMMUNIC INC4525EP101COM1,072,288$3,388,000thousands by filing date
THESEUS PHARMACEUTICALS INC88369M101COM504,862$2,928,000thousands by filing date
OTONOMY INC68906L105COM2,312,880$682,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001892688-22-000084this filing2022-11-14acceptance time not in the bulk data set